Obesity drug advances and health assessment

A July 22 review of 262 randomized trials involving nearly 100,000 adults found that the newest anti‑obesity medicines—particularly tirzepatide and semaglutide—produce the greatest weight loss but also raise rates of gastrointestinal side effects and loss of lean muscle. Injectable semaglutide demonstrated clear reductions in all‑cause mortality, heart attacks and heart‑failure hospitalisations, while tirzepatide lowered heart‑failure risk; neither drug significantly cut kidney failure. A parallel study showed that modest weekly exercise (≈2½ hours) added cardiovascular benefits, such as reduced carotid‑wall thickness and improved vascular function, that medication alone did not provide.

Four days later, a Lancet Diabetes & Endocrinology commission highlighted that these drug breakthroughs are reshaping obesity management, moving the field away from a reliance on bariatric surgery. Researchers argued that weight loss alone does not guarantee metabolic health and called for a broader evaluation framework that includes body‑fat distribution, organ function, physical capacity and real‑world health impacts rather than sole reliance on body‑mass index.

Together, the snapshots trace the rapid emergence of highly effective pharmacologic obesity treatments, their mixed safety profile, and an emerging consensus that measuring success must expand beyond weight loss to encompass overall health outcomes.